Paper Details

  1. Home
  2. Paper Details

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.

Author: , ApazMaria-Teresa, BaildamEileen, BaloghZsolt, BeutlerAnna, ClarkJason, CutticaRuben, EspadaGraciela, FasanmadeAdedigbo, FasthAnders, GamirMaria Luz, GerloniValeria, GianniniEdward H, HenricksonMichael, JoosRik, KeenanGreg, LahdennePekka, LovellDaniel J, MarodiLaszlo, MartiniAlberto, McCurdyDeborah, MendelsohnAlan, MyonesBarry L, NagyKalman, PettyRoss E, PrieurAnne-Marie, RavelliAngelo, RaychaudhuriAparna, ReumanPeter, RupertoNicolino, SaurenmannRotraud K, SilvermanEarl D, SzerIlona, TraversSuzanne, VisvanathanSudha, WilkinsonNick, WooPatricia, WoutersCarine, WulffraatNico, ZulianFrancesco

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Infliximab showed durable efficacy for juvenile rheumatoid arthritis (JRA) at 1 year, with both the 3 mg/kg and 6 mg/kg doses achieving significant improvements in disease activity. However, the 3 mg/kg dose was associated with more frequent serious adverse events, infusion reactions, and antibody development, suggesting a more favorable risk/benefit profile for the 6 mg/kg dose.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid arthritis (JRA). METHODS: This was an international, multicenter, randomized, placebo-controlled, double-blind study. One hundred twenty-two children with persistent polyarticular JRA despite prior ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/art.22838

データ提供：米国国立医学図書館（NLM）

Infliximab for Juvenile Rheumatoid Arthritis: A New Hope for Young Patients

The field of [rheumatology] is dedicated to finding effective treatments for [juvenile rheumatoid arthritis (JRA)]. This study investigates the use of [infliximab] in combination with [methotrexate (MTX)] for treating [polyarticular-course JRA]. The researchers found that [infliximab] showed durable efficacy in reducing [JRA] symptoms, but they also observed some safety concerns associated with the lower dose of [infliximab].

Infliximab: A Promising Treatment for JRA, But With Cautions

This study provides evidence that [infliximab] can be an effective treatment for [polyarticular-course JRA]. The researchers found that a higher proportion of patients receiving [infliximab] achieved significant improvements in their [JRA] symptoms compared to those receiving placebo. However, they also noted some potential safety concerns associated with the lower dose of [infliximab], suggesting that the higher dose may be more favorable. This highlights the importance of careful monitoring and individualized dosing for patients receiving [infliximab].

A Light in the Desert of JRA

Imagine [JRA] as a persistent desert sandstorm, causing pain and discomfort for young patients. [Infliximab] acts like a calming oasis, offering relief from the relentless storm. This study offers hope for young patients battling [JRA], but emphasizes the importance of considering both the potential benefits and risks of this medication.

Dr.Camel's Conclusion

This study provides promising evidence for the use of [infliximab] in treating [polyarticular-course JRA]. While [infliximab] showed durable efficacy in reducing [JRA] symptoms, the researchers also highlighted potential safety concerns associated with the lower dose. This underscores the importance of careful monitoring and individualized dosing when using [infliximab]. The fight against [JRA] is ongoing, and this research offers valuable insights into the potential benefits and risks of this treatment, paving the way for improved care for young patients.

Date :
  1. Date Completed 2007-11-27
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

17763439

DOI: Digital Object Identifier

10.1002/art.22838

Related Literature

Article Analysis
・Effective treatment of rheumatoid arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.